PureTech Health PLC Total Voting Rights (8677L)
January 02 2019 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 8677L
PureTech Health PLC
02 January 2019
2 January 2019
PureTech Health plc
Total Voting Rights and Share Capital - Month End Disclosure
Pursuant to DTR 5.6.1 of the Disclosure Guidance and
Transparency Rules:
As at 31 December 2018 the issued share capital of PureTech
Health plc comprised 282,493,867 Ordinary shares of one pence each.
There were no shares held in treasury.
The total number of voting rights in PureTech Health plc is
therefore 282,493,867.
This information may be used by shareholders in their
calculations to determine if they are required to notify their
interest in, or a change to their interest in, PureTech Health plc
under the FCA's Disclosure Guidance and Transparency Rules.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep
insights into the connection between the individual components of
these systems and the resulting role in many chronic diseases,
which have proven resistant to established therapeutic approaches.
By harnessing this emerging field of human biology, PureTech Health
is developing new categories of medicines with the potential to
have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions: the Affiliates division and the
Internal division. Its Affiliates division includes two product
candidates that have been filed with the US Food and Drug
Administration (FDA) for review and several other novel clinical
and pre-clinical programmes. These affiliates are developing
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading experts.
PureTech's Internal division is advancing a pipeline fuelled by
recent discoveries in lymphatics and immune cell trafficking to
modulate disease in a tissue-specific manner. These programmes
leverage the transport and biodistribution of various immune system
components for the targeted treatment of diseases with major unmet
needs, including cancers, autoimmune diseases, and neuroimmune
disorders.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
PureTech Health FTI Consulting
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRUGUQAGUPBGBG
(END) Dow Jones Newswires
January 02, 2019 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024